7.21
-0.3(-3.99%)
Currency In USD
| Previous Close | 7.51 |
| Open | 7.33 |
| Day High | 7.46 |
| Day Low | 7.16 |
| 52-Week High | 8.36 |
| 52-Week Low | 2.2 |
| Volume | 73,707 |
| Average Volume | 1.04M |
| Market Cap | 28.44M |
| PE | -0.75 |
| EPS | -9.67 |
| Moving Average 50 Days | 4.4 |
| Moving Average 200 Days | 3.66 |
| Change | -0.3 |
If you invested $1000 in Athira Pharma, Inc. (ATHA) since IPO date, it would be worth $42.14 as of December 24, 2025 at a share price of $7.21. Whereas If you bought $1000 worth of Athira Pharma, Inc. (ATHA) shares 3 years ago, it would be worth $241.95 as of December 24, 2025 at a share price of $7.21.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million
GlobeNewswire Inc.
Dec 18, 2025 12:02 PM GMT
Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Financing Co-Led by Commodore Capital, Perceptive Advisors an
Athira Pharma Announces Reverse Stock Split
GlobeNewswire Inc.
Sep 11, 2025 1:00 PM GMT
BOTHELL, Wash., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (“Athira” or “Company”) (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, t
Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025
GlobeNewswire Inc.
Aug 14, 2025 11:00 AM GMT
BOTHELL, Wash., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, presented results from its